Compared with HIV-associated diffuse large B-cell lymphoma, PEL was associated with significant hypoalbuminemia (<i>P</i> < .0027), thrombocytopenia (<i>P</i> = .0045), and elevated IL-10 levels (<i>P</i> < .0001).
In the seven children who developed shock with NPMODS compared to eight patients with shock without NPMODS and 12 patients with severe sepsis only, we found more profound coagulopathy [thrombocytopenia (<i>p</i> = 0.04), elevated INR (<i>p</i> = 0.038), low fibrinogen level (<i>p</i> = 0.049), and low TEG-G value (<i>p</i> = 0.01)] and higher peak of interleukin-6 (<i>p</i> = 0.0014) and IL-10 (<i>p</i> = 0.007).
IL-10 serum levels and IL-10 promoter polymorphic genotype frequencies are not different between ITP cases and controls; however, in ITP patients, IL-10 promoter (1082 AA and 592 AA) genotypes and associated lower CD4, higher CD8, lower CD4/CD8 ratio is associated with more severe thrombocytopenia at presentation and had a poorer response to first-line treatment.
The results showed that after treatment, the number of Treg cells was increased, the number of Th17 cells was decreased, the levels of anti-inflammatory factors IL-10 and TGF-β were increased, and levels of pro-inflammatory factors IL-17, IL-21 and IL-22 were decreased in chronic hepatitis B patients combined with thrombocytopenia, indicating the decreased autoimmune response and improved thrombocytopenia.
A subset of cytokines consisting of IL-1β, IL-8, IL-6, TNF-α, and IL-10 was also coordinately high and significantly associated with severity of thrombocytopenia in HA patients.
According to our data, patients with low producer type of IL-10 polymorphisms have more severe thrombocytopenia, suggesting that IL-10 gene polymorphisms may reflect the severity of ITP.